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Abstract
Mutations at the bilirubin UDP-glucuronosyltransferase (transferase) gene in a severely hyperbilirubinemic Crigler-Najjar
(CN) type I individual was compared with that in a moderately hyperbilirubinemic CN II individual. The CN-I (CF) patient
in this study sustained a TATA box insertional mutation which was paired with a coding defect at the second allele, unlike all
coding defects previously seen in CN-I patients. The sequence of the mutant TATA box, [A(TA)8A], also seen in the CN-II
patient, was compared with that at the wild-type box, [A(TA)7A]. Transcriptional activity with [A(TA)8A] was 10^15% that
with the wild-type box when present in the 31.7 kb upstream regulatory region (URR) of the bilirubin transferase UGT1A1
gene which was fused to the chloramphenicol acetyl transferase reporter gene, pCAT 1.7H, and transfected into HepG2 cells.
Also, a construct with a TA deletion, [A(TA)6A], was prepared and used as a control ; transcriptional activity was 65%
normal. The coding region defect, R336W, seen in CF (CN-I) was placed in the bilirubin transferase UGT1A1 [HUG-Br1]
cDNA, and its corresponding protein was designated UGT1A1*32. The UGT1A1*32 protein supported 0^10% normal
bilirubin glucuronidation when expressed in COS-1 cells. The I294T coding defect seen at the second allele in SM (CN-II)
generated the UGT1A1*33 mutant protein which supported 40^55% normal activity with a normal Km (2.5 WM) for
bilirubin. The hyperbilirubinemia seen in SM decreased in response to phenobarbital treatment, unlike that seen in CF.
Parents of the patients were carriers of the respective mutations uncovered in the offspring. The TATA box mutation paired
with a deleterious missense mutation is, therefore, completely repressive in the CN-I patient, and is responsible for a lethal
genotype/phenotype; but when homozygous, i.e. paired with itself, as previously reported in the literature, it is far less
repressive and generates the mild Gilbert’s phenotype. z 1998 Elsevier Science B.V. All rights reserved.
Keywords: Crigler-Najjar types I and II; Bilirubin UDP-glucuronosyltransferase activity and gene; TATA box mutation;
Compound heterozygotes
1. Introduction
The potentially neurotoxic lipophilic-like bilirubin
is produced daily in high abundance from senescent
red blood cells and is detoxi¢ed in humans solely
through its conjugation to glucuronic acid via bilir-
ubin UDP-glucuronosyltransferase (transferase) cat-
alysis. The glucuronides formed have enhanced water
solubility and excretability from the cell. Diseases or
syndromes exist in humans re£ecting three levels of
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severity. Crigler-Najjar (CN) type I patients [1] are
known to contain essentially no detectable bilirubin
transferase activity, su¡er with a severe serum un-
conjugated hyperbilirubinemia (s 20 mg%), and are
at risk for lethal neurotoxicity due to kernicterus.
The less severely a¡ected CN-II patients have inter-
mediate levels of bilirubin transferase activity, man-
ifest an intermediate level of hyperbilirubinemia
(6 20 mg%), and are usually not susceptible to neu-
rotoxicity due to bilirubin accumulation [2]. Typi-
cally, the CN-II individuals, unlike the type I popu-
lation, respond to phenobarbital (PB) treatment [3]
by manifesting a reduction in serum bilirubin levels.
A substantial 5% of the population, classi¢ed as Gil-
bert’s individuals [4], are often asymptomatic but
have a mild hyperbilirubinemia (approx. 1.0^1.5
mg%) also due to a reduction in bilirubin transferase
activity [5]. Normal serum bilirubin levels range be-
tween 0.5 and 0.75 mg%. Like CN-II patients, some
Gilbert’s individuals have been shown to respond to
PB treatment [6]. Further, there are reports [7,8] in
the literature of CN individuals with serum bilirubin
levels consistent with that of the most serious type,
CN-I, reaching 40 mg% who responded to PB treat-
ment. These reports indicate that the hyperbilirubi-
nemic phenotypes do not adhere to a consistent pat-
tern.
The human UGT1 complex locus [9,10] composed
of at least 12 di¡erent UDP-glucuronosyltransferase
(transferase) (J.W. Cho, Q.-H. Gong, C. Potter, N.
Gholami and I.S. Owens, manuscript in preparation)
genes, includes that for the bilirubin transferase,
UGT1A1. Many alterations have been uncovered in
the coding region of this gene [11^21] for CN in-
dividuals and for Gilbert’s individuals [22,23]. We
report here that a TA insertion at the TATA box
element at one allele and a deleterious missense
mutation at the second one are responsible for CN
type I disease. The unusual TATA box element
for the UGT1A1 gene is composed of seven consec-
utive TA di-nucleotides [A(TA)7A] and is situated
37 nucleotides upstream from the cap site of its mes-
senger RNA [9]. A CN-II individual also sustained
this same TATA box mutation except there is a less
deleterious missense mutation at the second allele.
Further, this study allows us to contrast the pheno-
barbital response in the CN-I and CN-II pa-
tients.
2. Materials and methods
2.1. Reagents
The sources of reagents used to carry out recombi-
nant DNA techniques were previously reported
[11,13]. The TA vector was obtained from Invitrogen
(San Diego, CA). The sources of materials for the
transfection of plasmid DNA into the COS-1 cells
and the radiolabeling and immunoprecipitation of
the expressed bilirubin transferase protein have
been reported [24]. HepG2 cells were from ATCC
cell culture (Rockville, MD).
2.2. Clinical pro¢le for the CN-I (CF) and CN-II
(SM) individuals
CF is an Italian female spontaneously delivered
after an uneventful pregnancy. There was no mater-
nal use of medication or antepartum illnesses. On
day 2 jaundice was noted, and on day 5 total serum
bilirubin concentration was 312 WM (18.1 mg/dl).
Treatment with phenobarbital did not cause a de-
crease in serum bilirubin levels. A family history of
Gilbert’s syndrome ^ including the father but not the
mother ^ was found [25]. Phototherapy for 18 h/day
proved to be e¡ective in reducing and maintaining
bilirubinemia at an average of 12 mg/dl. Since the
patient did not respond to Sn-protoporphyrin treat-
ment or phenobarbital therapy at the age of 3.5 years
and continued to have a high serum unconjugated
bilirubin concentration by HPLC analysis, she was
recommended for and underwent liver transplant
surgery at that age. At the time of this writing the
patient was doing well.
SM is also Italian and unrelated to CF. SM was
hospitalized at 12 days of age because of intense
jaundice ¢rst noted on day 2 in the community hos-
pital. Gilbert’s syndrome was diagnosed in the ma-
ternal grandmother [26]. Phototherapy treatment was
initiated and caused a reduction in the unconjugated
bilirubin level. Phenobarbital (PB) (5 mg/kg b.wt./
day) was begun on day 15 and continued for 3 weeks
without any evident improvement. Subsequently, an
experimental trial was undertaken with intramuscu-
lar injection of Sn-protoporphyrin (2 Wmol/kg b.wt.)
administered when serum bilirubin concentration
rose to 20 mg/dl. The Sn-derivative was interrupted
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due to the appearance of erythema during photother-
apy. Three months later PB was again attempted,
and the positive response culminated in the de¢nitive
diagnosis of CN-II disease. Upon PB treatment the
serum bilirubin levels decreased, on average, to 7^8
mg/dl.
2.3. Preparation of genomic DNA and nucleotide
sequence analysis
Genomic DNA from leukocytes was prepared as
already described [11]. Regions of the UGT1A1 gene
was ampli¢ed by the polymerase chain reaction
(PCR), and subclones were sequenced as described
[11,17]. PCR ampli¢cation of the TATA box region
was carried out with sense primer PAGS1 and anti-
sense primer PAGA1 to generate a 317 bp fragment.
The sequence for PAGS1 is 5P-TTAACTTGGTG-
TATCGATTGGT-3P and that for PAGA1 is 5P-
GTCTTCAAGGTGTAAAA-3P. Exons in the
UGT1A1 gene were ampli¢ed with primers already
described [17]. For both CF and SM, ¢ve to ten
subclones representing either the non-coding or
each exon/£anking region were sequenced.
2.4. Determination of inheritance of TATA box
mutations
A 317 bp fragment encompassing the TATA box
element of the UGT1A1 gene of each genomic DNA
sample was ampli¢ed using PCR. The sense primer,
[32P]PAGS1 (7.5U106 cpm/pmol, 383 to 362 bp 5P
of the TATA box element), and antisense primer,
PAGA1 (+248^232 bp of the coding region of exon
1 of UGT1A1), were used. Fifty pmol of each primer
were used in the reaction; the ratio of non-labeled to
radiolabeled PAGS1 was 50. The products of the
reactions were separated by electrophoresis through
a 6% polyacrylamide gel which was exposed to X-ray
¢lm for development and print.
2.5. Construction of wild-type or mutant
pUGT1A1-cDNA expression units
All missense mutants were constructed in the
pSVL-based HUG-Br1-cDNA (now designated
pSVL-based UGT1A1) unit as previously described
[10]. Point mutations were introduced in the cDNA
at amino acid positions 294 and 336 and were des-
ignated I294T (UGT1A1*33) and R336W
(UGT1A1*32), respectively. The primer sets were
as follows: I294T, sense 5P-GAAGCCTACAC-
TAATGCTTC-3P and antisense 5P-GAAGCAT-
TAGTGTAGGCTTC-3P and R336W, sense 5P-GA-
CAGTCCTGTGGTGGTACA-3P and antisense 5P-
TGTACCACCACAGGACTGTC-3P. The outside
primers for all were sense OP170 and antisense
PXAS6 [17].
2.6. Expression of the bilirubin transferase by
wild-type or mutant pUGT1A1cDNA
constructs in COS-1 cells
COS-1 cells were plated in 100 mm dishes at 106
cells and grown to 90% con£uence in 24 h in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) with
HEPES bu¡er and 4% fetal calf serum (FCS). pUG-
T1A1 or each of its mutants was transfected into
cells using DEAE-dextran as the carrier as described
[17]. The transferase isozymes were radiolabeled dur-
ing the ¢nal 4 h of the incubation as previously de-
scribed by Ciotti et al. [17]. Goat anti-mouse UDP-
glucuronosyltransferase IgG was added to the solu-
bilized labeled cellular extract and processed for
SDS-gel electrophoresis as described [24]; the dried
gel was exposed to X-ray ¢lm for an autoradiograph.
[35S]Methionine incorporated into immunocom-
plexed protein was analyzed on SDS-polyacrylamide
gels which were dried and scanned on the Fuji Phos-
phorimager BAS 2000; the counts were used to es-
tablish equivalent amounts of wild-type and mutant
proteins for the glucuronidation reactions. The
amount of bilirubin-glucuronide on TLC plates was
analyzed on the Ambis Radioanalytical Imaging Sys-
tem Mark II as previously described [24]. X-Ray ex-
posures of the TLC plates were developed for radio-
grams.
2.7. Bilirubin transferase activity following
ransfection with the wild-type or mutant
pUGT1A1 constructs in COS-1 cells
Cell homogenate containing expressed wild-type or
mutant enzyme was used to determine bilirubin glu-
curonidating activity as described [13,17] with mod-
i¢cations. The reaction bu¡ers were standardized us-
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ing between 300 and 600 Wg cell homogenate pro-
tein as follows: for the pH 6.4 bu¡er, 0.1 M sodium
phosphate pH 8.05 was diluted to 20 mM and
adjusted to pH 6.4 with 0.65 Wl of 1.0 N NaOH/
300 Wg protein, and for the pH 7.6 bu¡er 0.166 M
triethanolamine pH 8.6 was diluted to 32 mM and
adjusted to pH 7.6 with 1.6 Wl of 1.0 N NaOH/300
Wg protein. In order to compare the e¡ect of
mutations on activity, equal amounts of speci¢c pro-
tein were required and established as described
above.
2.8. Construction of mutants in the TATA box
element of the UGT1A1 gene
The pCAT reporter gene was fused with either the
30.5 kb, 31.7 kb, or 32.9 kb upstream region of the
wild-type UGT1A1 gene generating constructs desig-
nated pCAT/0.5PstI, pCAT/1.7HindIII, or pCAT/
2.9XbaI, respectively. Also, the 2.9 kb fragment
was inserted in the reverse orientation
(pCAT2.9X(R). The wild-type TATA box element
in each of the three constructs is A(TA)7A. The 3P
end (NarI site) of the £anking region is 36 bp down-
stream from the TATA box. The pCAT basic and
pCAT-enhancer vector used in Fig. 7A were modi-
¢ed to reduce the background as seen in Fig. 7C
according to Lei et al. [27]. Mutants in the pCAT/
1.7 kb HindIII contained either A(TA)8A or
A(TA)6A. To make the mutant TATA box elements,
a 317 bp fragment was ampli¢ed from the genomic
DNA isolated from CF and SM using the sense pri-
mer PAGS1 and the antisense primer, PAGA1. A
second more 5P fragment which overlapped by 22
bp was ampli¢ed with sense primer 5P-UPBr13 (5P-
GAGCTTTAATTGGTTGGT-3P (3975 to 3958
bp)) and antisense primer 5P-UPBr1-21 (5P-AC-
CAATCGATACACCAAGTTAAT-3P (363 to 385
bp)) to generate a 919 bp fragment. The ampli¢ed
fragment overlapped the PAGS1 primed sequence by
22 bp. The two interchanged hybridizing fragments
were used in a second PCR with the outside sense
primer, 5P-UPBr1-3, and antisense primer, 5P-AUP-
Br1 (5P-CCTTTGCTCCTGCCAGAGGTTC-3P, 35
to 325 bp) nested with PAGA1 to generate a 969
bp fragment which was digested with StuI and Eco-
NI and subcloned into StuI/EcoNI-digested pCAT/
1.7HindIII-based unit. The 969 bp fragment was se-
quenced to verify that no other changes had oc-
curred.
2.9. Transcriptional activity generated by the
pCAT constructs in the HepG2 cells
HepG2 cells were plated in 100 mm dishes at 106
and grown in Eagle’s medium with HEPES bu¡er
and 4% fetal calf serum (FCS) to 90% con£uence
in 24 h. pCAT constructs were transfected into the
cells by the calcium phosphate coprecipitation meth-
od [28]. Twenty Wg of each pCAT construct were
mixed with 500 Wl 2UHEBS bu¡er, pH 7.05, and
while shaking the samples, 500 Wl of Ca-chloroquine
were added dropwise (2 M CaCl2 ; 40 WM chloro-
quine). The mixture was allowed to stand at room
temperature for 30 min before adding directly to the
cells. After 5 h of incubation at 37‡C the medium
was replaced with fresh medium. Cells were har-
vested 72 h later and analyzed for acetylchloram-
phenicol activity.
2.10. Acetylchloramphenicol activity generated by
wild-type and mutant pCAT/HindIII reporter
gene constructs in HepG2 cells
Acetylchloramphenicol transferase activity ex-
pressed by the reporter gene in HepG2 cells was
measured as described [29]. The assay conditions
were optimized for cellular extract and incubation
time as shown in Fig. 7A,B.
3. Results
3.1. Defects in the coding region of the CN-I and the
CN-II patients
In order to determine the cause of the hyperbili-
rubinemia in the CN-I (CF) and the CN-II (SM)
patients, we sequenced ¢ve to ten di¡erent subclones
for each of the ¢ve exons of the UGT1A1 gene [9].
Fig. 1A shows that a C to T transition changed an
Arg to Trp at codon 336 (R336W) in two out of six
subclones for CF. All other exons from CF were
normal. The C to T transition at codon 336 was
present in one out of ¢ve subclones of the DNA
from the mother of CF.
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In the CN-II (SM) individual (Fig. 1B), a T to C
transition changed an Ile to Thr at codon 294
(I294T) in two out of ¢ve subclones for SM. All
other subclones representing the UGT1A1 gene re-
vealed no other coding alterations. The T to C tran-
sition at codon 294 was present in one out of ¢ve
subclones for the father of SM. Altered codons
294 and 336 are located in exon 2 and 3, respec-
tively.
3.2. Expression of wild-type and mutant bilirubin
transferase proteins and the e¡ects of mutations
on glucuronidation
Several missense mutations have been demon-
strated to cause essentially a total loss of bilirubin
activity in CN-I patients [11^13,17]. The e¡ect of
mutations seen in CN-II patients on bilirubin trans-
ferase activity has been documented in only one case
[21]. Also, we would like to account for the di¡erence
in severity of hyperbilirubinemia in these two pa-
tients in the wake of a common mutation and di¡er-
ences in response to phenobarbital treatment. Ex-
pression of wild-type and mutant transferase in
COS-1 cells was established by immunocomplex for-
mation (Fig. 2). Furthermore, we quantitated the
amount of speci¢c protein produced by each con-
struct by analysis on the phosphorimager as de-
scribed above. The results were used to establish
equal amounts of speci¢c protein for glucuronidation
studies.
Fig. 2. Immunocomplexes of the UGT1A1 protein and its mu-
tants, UGT1A*32 and UGT1A1*33, synthesized in COS-1 cells.
Cells were transfected with either pUGT1A1, pUGT1A1*32, or
pUGT1A1*33 expression units and incubated for 72 h. The
proteins were radiolabeled for the ¢nal 4 h with
[35S]methionine, solubilized, and immunocomplexed with goat
anti-mouse UDP-glucuronosyltransferase as described in Section
2. (It has been established that the HUG-Br1 (UGT1A1)
cDNA encodes a 52 kDa protein in COS-1 cells which is immu-
nocomplexed with this antibody [13,17].) Washed product was
separated on a SDS-polyacrylamide gel during electrophoresis
and dried; the speci¢c bands were quantitated by scanning on
a phosphorimager as described in Section 2.
Fig. 1. Comparison of nucleotide sequences in a wild-type
UGT1A1 (HUG-Br1) cDNA with that of UGT1A1*32
(R336W; CN-I) and UGT1A1*33 (I294T; CN-II) mutants. Se-
quencing reactions of a normal exon 3 (top left) and that from
a CN-I (CF) patient code for the wild-type UGT1A1cDNA
and the mutant UGT1A1*32, respectively. Also, a normal exon
2 (bottom left) is compared with that from a CN-II (SM) indi-
vidual (bottom right) which codes for the UGT1A1*33 mutant.
Sequencing determinations were as described in Section 2. The
sequencing ladders were generated by electrophoresis through
6% denaturing polyacrylamide gels, blotted, dried, and exposed
to X-ray ¢lm for the autoradiogram. A, C, G, and T represent
reactions stopped with dideoxy derivatives of ATP, CTP, GTP,
and TTP, respectively. The solid circle represents the substituted
nucleotide in the patient genome.
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In Fig. 3, the results are shown for bilirubin glu-
curonidation when carried out at both pH 6.4 and
7.6. For wild-type UGT1A1, there is 3-fold more
product formed at pH 6.4 than at pH 7.6. The
R336W coding mutation in the CN-I patient ex-
pressed no activity at pH 6.4, but had 12% normal
activity at pH 7.6.
Under each pH condition, the I294T missense mu-
tation in the CN-II individual caused a partial loss of
activity. At pH 6.4, 45% of the activity remained,
and at pH 7.6 59% remained. For the wild-type pro-
tein, the physiological signi¢cance of 2^3-fold more
measurable activity at pH 6.4 compared to that at
the more typical condition of pH 7.6 is not under-
stood. The results show that the I294T mutant pro-
tein has far superior activity (overall some 50% of
normal) at both pH 7.6 and 6.4 compared to the
R336W mutant (0^10% normal). Hence, the missense
mutation in the CN-I patient is far more debilitating
than that in the CN-II patient.
Also, the I294T mutant of the UGT1A1 protein
was assessed for its a⁄nity toward bilirubin. Fig. 4
shows that the Km for bilirubin is approx. 2.5 WM at
both pH 6.4 and pH 7.6. While the Vmax for bilirubin
glucuronidation was decreased, its a⁄nity for biliru-
bin was essentially normal [13].
3.3. Demonstration of mutations in the TATA
box element
The unusual TATA box element upstream from
the bilirubin transferase gene, UGT1A1, was shown
[9] to contain seven consecutive TA di-nucleotides as
Fig. 4. Relative reaction velocity versus bilirubin concentration
of the UGT1A1*33 enzyme. Glucuronidation reactions at both
pH 6.4 and 7.6 were carried out with bilirubin between 2.5 and
100 WM for 2 h at 37‡C and analyzed as described in the
legend to Fig. 3.
Fig. 3. Catalysis of bilirubin glucuronidation by UGT1A1, UGT1A1*32, and UGT1A1*33 at both pH 6.4 and 7.6. COS-1 cells were
transfected as described in the legend to Fig. 2. The same amount of speci¢c protein for UGT1A1, UGT1A1*32, (CN-I), and
UGT1A1*33 (CN-II) was used to determine bilirubin glucuronidation at both pH 6.4 and 7.6 as described in Section 2. The assays,
containing 1.4 mM [14C]UDP-glucuronic acid (1.4 WCi/Wmol) and 100 WM bilirubin, were incubated at 24‡C for 16 h, and product
was analyzed as described in Section 2. Bilirubin glucuronides separated on TLC plates were exposed to X-ray ¢lm, developed, and
printed for autoradiograms. All ¢lms were exposed for 14 days.
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follows: ATATATATATATATAA [A(TA)7A] (Fig.
5, left ladder). Also, Fig. 5 shows a representative
sequence ladder across the TATA box element that
was observed for two out of ¢ve subclones for the
CN-I (CF) genome and two out of ¢ve subclones for
the CN-II (SM) genome. Hence, a TA insertion,
[A(TA)8A], was detected at one allele for both pa-
tients. Since each patient also contained a coding
region defect, described above, one can conclude
that each is a compound heterozygote.
3.4. Inheritance of the TATA box mutation by
CF and SM
In the 6% polyacrylamide gel, as shown in Fig. 6,
the PCR-ampli¢ed TATA box region of the normal
individual (lane 1) generated a single 317 bp frag-
ment. This 317 bp fragment, diagnostic for the nor-
mal TATA box, was present in every sample. The
TA insertion in the TATA box generated a distinct
band for the predicted 319 bp fragment at a position
equivalent to 2 bp above the typical 317 bp fragment
as seen for both probands (Fig. 6, CF, lane 2, and
SM, lane 5). The father (lane 3) of CF and the moth-
er (lane 7) of SM are also carriers of the TA in-
sertion. Hence, CF inherited the R336W missense
mutation and the TA insertion, [A(TA)8A], from
her mother and father, respectively. SM inherit-
ed the I294T coding defect and the [A(TA)8A]
mutant TATA box from her father and mother, re-
spectively. There is no kindred among the two fam-
ilies.
3.5. Transcriptional e¡ects of TATA box mutations of
the UGT1A1 upstream regulatory region fused to
the pCAT reporter gene
Initially, we determined the minimum upstream
region of the UGT1A1 gene required to generate
maximum transcriptional activity in the pCAT re-
porter gene assay. The upstream-reporter gene con-
structs were transfected into HepG2 cells as de-
scribed; cells were harvested and analyzed for
acetyl chloramphenicol (CAT) activity. Fig. 7A (ar-
row) shows that the pCAT/1.7HindIII with the 31.7
kb upstream regulatory region generated greater ac-
tivity than pCAT/2.9XbaI with a 32.9 kb URR. The
relative counts demonstrated that the 1.7 kb frag-
ment was 2.5-fold more active than the 2.9 kb and
3.1-fold more active than the pCAT/0.5PstI with a
30.5 kb URR (data not shown). Also, we estab-
lished the optimal protein and time course for the
CAT activity (Fig. 7B). Since the background was
shown to be signi¢cant in Fig. 7A (arrow, pCAT
Basic), the vectors were modi¢ed as described in Sec-
tion 2 to reduce read-through as shown in Fig. 7C
(arrow, pCAT Basic).
Fig. 5. Sequences surrounding the TATA box element of the
gene from a normal and a defective element seen in both a
CN-I (CF) and a CN-II (SM) individual. Sequence determina-
tions were as described in Section 2. The sequencing ladders
were generated and analyzed as described in the legend to Fig.
1. A normal element, A(TA)7A, and the insertion mutant box,
A(TA)8A, were seen in both CN-I and CN-II patients. A dele-
tion mutant TATA box, A(TA)6A, was constructed to use as a
control and was sequenced.
Fig. 6. Inheritance of the TA insertion at the TATA box of the
bilirubin transferase gene by CF and SM. Genomic sequences
surrounding the TATA box of the UGT1A1 gene of a control
(Ct), the probands (Pb), and their respective mother (Mr) and
father (Fr) were ampli¢ed by PCR using the sense primer,
[32P]PAGS1, and the antisense primer, PAGA1, as described in
Section 2. The radiolabeled product was separated on a 6% pol-
yacrylamide gel as described in Section 2 and exposed to X-ray
¢lm which was developed and printed. The 317 bp fragment
represents wild-type and the 319 fragment represents the mutant
TATA box element with TA di-nucleotide insertion.
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The results in Fig. 7C show that transcriptional
activity with the A(TA)8A promoter element is 89%
reduced and that for the A(TA)6A is 33% reduced.
For three experiments the range of inhibition was
85^89%.
Fig. 7D shows that seven TAs are the optimal
number to generate the highest transcriptional activ-
ity in vitro. Although we expected to ¢nd deletions at
the TATA box, 20 randomly selected individual
DNA samples examined contained no mutation of
any type at the TATA box. This compares to a re-
port of 51% frequency (28/55 individuals) of hetero-
zygotes with the insertional mutation at the TATA
box in the population [23].
4. Discussion
We have shown that a TA di-nucleotide insertional
mutation at the expansive TATA box element,
A(TA)7A, of the bilirubin transferase gene,
UGT1A1, exists in the compound heterozygous state
in both a CN-I and a CN-II hyperbilirubinemic pa-
tient. The potentially lethal CN-I disease has been
documented in reports [11^17] to be an autosomal
recessive disease requiring a deleterious mutation in
both alleles of the UGT1A1 bilirubin transferase gene
to account for essentially a total loss of bilirubin
transferase activity in patients. All such mutations
in the high-risk CN-I population were previously
found in the coding region of the bilirubin transfer-
Fig. 7. E¡ect of the wild-type TATA box, A(TA)7A, versus the mutant boxes, A(TA)8A and A(TA)6A, on transcriptional activity as-
sessed with the UGT1A1 promoter region-CAT reporter gene constructs transfected into HepG2 cells. (A) Transcriptional activity,
measured by product (arrow) generated by pCAT basic reporter gene or the pCAT/enhancer control, is compared with that by pCAT
basic constructs which contained either the 30.56 bp, 31.7 bp or 32.9 bp upstream £anking region of the UGT1A1 gene. The 32.9X
(R) is in the reversed orientation. (B) Time course of transcriptional activity estimated by CAT product supported by the pCAT basic
vector with either the wild-type TATA box (ATA7A) designated pCAT1.7H, the TA deletion mutant (ATA6A) box designated
pCAT1.7H6TA, and the TA insertion mutant (ATA8A) box designated pCAT1.78TA in the 31.7 bp upstream £anking region of the
UGT1A1 gene. Product is denoted with the arrow. (C) Product (arrow) of CAT activity is evaluated as counts/min generated with the
same experimental constructs used in B. The plot in D represents the relative e¡ectiveness of the number of TAs in the TATA box el-
ement on transcriptional activity contained in the 31.7 bp upstream region/pCAT construct.
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ase gene. In this study, the TA insertion destroyed
85^89% transcriptional activity as measured in vitro,
presumably, re£ecting in vivo transcription at one
allele in both the CN-I and II patients. The missense
mutation substituting R336W in the CN-I patient
expressed no detectable activity at pH 6.4 and 12%
normal activity at pH 7.6. In the CN-I patient, it is
predicted that the UGT1A1*32 (R336W) protein is
essentially totally inactive and that there is more
than 85^89% loss of transcriptional activity by the
A(TA)8A box mutation to create the severe hyper-
bilirubinemic condition of CF. Hence, it is likely that
both mutations are completely deleterious in the CN-
I individual.
The CN-II disease is far less severe due to residual
bilirubin glucuronidating activity [2] ; here we show
that this is most likely due to a mutation that parti-
ally inactivates the bilirubin transferase encoded at
the second allele. The missense mutation substituting
I294T in the CN-II individual exhibited some 50%
normal activity at pH 6.4 and 7.6, respectively, and
normal a⁄nity (Km = 2.5 WM) for bilirubin. For the
CN-II patient, it is predicted that the substantially
more active UGT1A1*33 (I294T) protein paired with
greater than 85% loss of transcriptional activity at
the allele with the mutant TATA box are responsible
for the less threatening hyperbilirubinemic phenotype
of SM.
Repetitive treatment of CF with phenobarbital up
to 3.5 years of age failed to elicit a decrease in serum
bilirubin levels. Hence, this patient received a liver
transplant at that age. Since the hyperbilirubinemia
seen in SM, and not that of CF, did respond to
phenobarbital treatment, it is predicted that in-
creased synthesis of the partially active protein,
I294T, by phenobarbital is responsible for bringing
about the decrease in serum bilirubin in SM. The
drug had the potential to increase, at best, the syn-
thesis of an essentially inactive R336W protein in the
CN-I patient. Based on the outcome of the drug
treatment in the two patients, it does not appear
that the TATA box mutation responded to pheno-
barbital.
Although Gilbert’s individuals have been reported
[6] to respond to phenobarbital treatment, the geno-
types of the responders are unknown. Genotypes for
Gilbert’s are shown to include missense mutations
[22] as well. This population of individuals was re-
ported in a much earlier study [5] to have from 10 to
33% bilirubin conjugating activity remaining and,
presumably, that same amount of the transferase
protein.
Although the e¡ects of the TA insertion on in
vitro transcription were similar between this study
and that for the Gilbert’s case [23], the controlled
HepG2 cell culture conditions in the absence of sig-
ni¢cant amounts of the bilirubin transferase protein
may not re£ect actual in vivo transcriptional condi-
tions/e¡ects seen in the patients. The benign e¡ect of
the homozygous TA insertional mutation in Gilbert’s
individuals [23] and the evidently complete repression
of transcription in the CN-I patient of this study
suggest, however, that the e¡ect of this regulatory
mutation in vivo is quite variable and allows for
the full range of hyperbilirubinemic phenotypes.
This mutation may be analogous to the variable
[30,31] and unpredictable [32] transcriptional/transla-
tional e¡ects of the CGG-repeat expansion in the 5P
upstream region of the FMR1 gene among patients
with the fragile X syndrome. Frequently, the result-
ing CpG island is hypermethylated. While methyl-
ated versus unmethylated DNA in the 5P upstream
region harboring the 200-fold CGG-repeat expansion
generated only slight di¡erences in mRNA levels,
there was a complete lack of CAT activity with the
introduction of the repeats [30^32] as measured in
cell culture conditions. Hence, this regulatory model
for the mutation at the FMR1 gene leading to fragile
X syndrome inexplicably exhibited repressed CAT
activity based on mRNA levels. A consideration is
whether the mutant TATA box in the CN patients is
a¡ected by the level of the bilirubin isozyme (estim-
ably 50% of normal but with defective activity),
whereas Gilbert’s individuals have, estimably, 10^
33% normal enzyme levels. Further, it is not obvious
that cellular unconjugated bilirubin concentrations
could a¡ect the level of enzyme/activity in the pa-
tients studied.
Since it is possible that a TA deletion could also
occur in this unusually long TATA box element, the
transcriptional activity of A(TA)6A was examined.
The TA deletion proved to be less deleterious; a
35% decrease in transcription activity compared to
s 85% for the insertional mutation. It is possible
that the number of TAs present at the TATA box
a¡ects the binding/alignment of the transcriptional
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machinery and the transcription start site at the
UGT1A1 gene in the DNA molecule with intrinsic
helical structures for consideration.
Although the homozygous TA insertion de¢nes
the mild Gilbert’s syndrome [23], this study points
to the most dire outcome of this mutation in the
population. Individuals who are carriers (51%) [23]
of the TA mutation, like CF’s father, do have the
potential to generate o¡spring with a lethal geno-
type. Hence, this regulatory mutation, mild in Gil-
bert’s and deleterious in the CN-I and CN-II indi-
viduals in this study, is more complicated than the
missense mutations and does warrant consideration
as an issue for genetic counseling.
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